Early-stage clinical trial investigating the individual and combined effect of two drugs, senicapoc and perampanel, as part of the treatment for newly diagnosed glioblastoma, which is an aggressive brain tumor

2025-522605-37-00 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 1 Mar 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 36
Countries 1
Sites 1

Glioblastoma

Key facts

Sponsor
Region Midtjylland
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10], Phenomena and Processes [G] - Genetic Phenomena [G05], Diseases [C] - Neoplasms [C04]
Trial duration
1 Mar 2026 → ongoing
Decision date (initial)
2025-10-14
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma

VersionLevelCodeTermSystem organ class
20.0 PT 10018336 Glioblastoma 100000004864
21.1 PT 10065443 Malignant glioma 100000004864
20.0 PT 10018337 Glioblastoma multiforme 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Region Midtjylland

Sponsor organisation
Region Midtjylland
Address
Palle Juul-Jensens Boulevard 99
City
Aarhus N
Postcode
8200
Country
Denmark

Scientific contact point

Organisation
Region Midtjylland
Contact name
Anders Rosendal Korshøj, MD, PhD Consultant, Associate Professor, Department of Neurosurgery

Public contact point

Organisation
Region Midtjylland
Contact name
Henriette Thygesen, Research Secretary, Department of Neurosurgery

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruiting 36 1
Rest of world 0

Investigational sites

Denmark

1 site · Ongoing, recruiting
Region Midtjylland
Department of Neurosurgery, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2026-03-01 2026-03-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-09 Denmark Acceptable
2025-10-10
2025-10-14